Physician profile
Mark E Ginther
NPI 1669576146
$1,644.08
in general payments reported to CMS, 2019-2025
27 companies · $16.30 in 2025
The $16.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $167 · 2021: $340 · 2022: $221 · 2023: $219 · 2024: $182 · 2025: $16.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $322.69 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $229.95 | 2019-2021 | |
| Novo Nordisk INC | $187.26 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $125.00 | 2021 | |
| Abiomed | $115.55 | 2023 | Impella |
| Glaxosmithkline, LLC. | $96.16 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $93.19 | 2023-2024 | Airsupra, Farxiga, Breztri |
| Dexcom, INC. | $64.77 | 2021-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.69 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $40.04 | 2020 | |
| Harmony Biosciences LLC | $37.62 | 2021 | |
| Sanofi-Aventis U.S. LLC | $32.20 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.73 | 2022 | |
| Amarin Pharma, INC. | $21.79 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.59 | 2019 | |
| Abbvie INC. | $18.98 | 2024 | |
| Horizon Therapeutics Plc | $18.14 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.14 | 2022 | |
| Inspire Medical Systems, INC. | $16.30 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $14.99 | 2023 | Seglentis |
| E.R. Squibb & Sons, L.L.C. | $14.30 | 2022 | |
| Astellas Pharma US INC | $14.17 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.11 | 2019 | |
| Exact Sciences Corporation | $13.94 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.04 | 2019 | |
| Biodelivery Sciences International, INC. | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ginther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.